Meeting
2023 ASCO Annual Meeting
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Authors
Doris K. Hansen
Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
Doris K. Hansen , Krina K. Patel , Lauren C. Peres , Mehmet H. Kocoglu , Leyla Shune , Gary Simmons , Christopher J. Ferreri , Shebli Atrash , Ricardo Daniel Parrondo , Saurabh Chhabra , Patrick Costello , Shonali Midha , Melissa Alsina , Peter M. Voorhees , Myo Htut , Douglas W. Sborov , Jack Khouri , Murali Janakiram , Yi Lin , Surbhi Sidana
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8012)
DOI
10.1200/JCO.2023.41.16_suppl.8012
Abstract #
8012
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.
First Author: Hermann Einsele
Poster
2024 ASCO Annual Meeting
OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Robert M. Rifkin
Poster
2022 ASCO Annual Meeting
Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
First Author: Doris K. Hansen
Poster
2021 ASCO Annual Meeting
Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
First Author: Thomas G. Martin